journal article·2017-04Open access

Cell adhesive peptides functionalized on CoCr alloy stimulate endothelialization and prevent thrombogenesis and restenosis

Maria Isabel Castellanos, Jordi Guillem‐Marti, Carlos Mas‐Moruno, Maribel Díaz‐Ricart, Ginés Escolar, Maria Pau Ginebra, Francisco Javier Gil, Marta Pegueroles, Jose María Manero

Abstract

Abstract Immobilization of bioactive peptide sequences on CoCr surfaces is an effective route to improve endothelialization, which is of great interest for cardiovascular stents. In this work, we explored the effect of physical and covalent immoblization of RGDS, YIGSR and their equimolar combination peptides on endothelial cells (EC) and smooth muscle cell (SMC) adhesion and on thrombogenicity. We extensively investigated using RT‐qPCR, the expression by ECs cultured on functionalised CoCr surfaces of different genes. Genes relevant for adhesion (ICAM‐1 and VCAM‐1), vascularization (VEGFA, VEGFR‐1 and VEGFR‐2) and anti‐thrombogenicity (tPA and eNOS) were over‐expressed in the ECs grown to covalently functionalized CoCr surfaces compared to physisorbed and control surfaces. Pro‐thrombogenic genes expression (PAI‐1 and vWF) decreased over time. Cell co‐cultures of ECs/SMCs found that functionalization increased the amount of adhered ECs onto modified surfaces compared to plain CoCr, independently of the used peptide and the strategy of immobilization. SMCs adhered less compared to ECs in all surfaces. All studied peptides showed a lower platelet cell adhesion compared to TCPS. Covalent functionalization of CoCr surfaces with an equimolar combination of RGDS and YIGSR represented prevailing strategy to enhance the early stages of ECs adhesion and proliferation, while preventing SMCs and platelet adhesion. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 105A: 973–983, 2017.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cell Adhesion Molecules Research · Angiogenesis and VEGF in Cancer · Protease and Inhibitor Mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Biomaterials Biomechanics and Tissue Engineering Group, Department of Materials Science and Metallurgical Engineering, ETSEIB, Technical University of Catalonia (UPC) Barcelona 08028 Spain

Centre for Research in NanoEngineering (CRNE) UPC Barcelona 08028 Spain

Hemotherapy–Hemostasis Department Centre de Diagnòstic Biomèdic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic, Universitat de Barcelona Barcelona 08036 Spain

Institute for Bioengineering of Catalonia (IBEC) Barcelona 08028 Spain

Universitat Internacional de Catalunya (UIC) Barcelona 08017 Spain

Funding

Spanish Government · Agency for Administration of University and Research Grants of the Government of Catalonia · Health Institute Carlos III (ISCIII): Health Technological Development · Government of Catalonia; Generalitat de Catalunya

References (54)

Show source-provided references
1. 10.1373/clinchem.2007.09736010.1373/clinchem.2007.097360 ↗
2. 10.1161/01.RES.0000264509.36234.5110.1161/01.RES.0000264509.36234.51 ↗
3. 10.1016/j.nano.2009.09.00410.1016/j.nano.2009.09.004 ↗
4. 10.1016/j.ijpharm.2012.10.02910.1016/j.ijpharm.2012.10.029 ↗
5. 10.1016/j.jacc.2010.05.06610.1016/j.jacc.2010.05.066 ↗
6. 10.1161/01.CIR.86.6.183610.1161/01.CIR.86.6.1836 ↗
7. 10.1016/j.jacc.2009.10.07010.1016/j.jacc.2009.10.070 ↗
8. 10.1161/01.CIR.0000163587.36485.A710.1161/01.CIR.0000163587.36485.A7 ↗
9. 10.1038/nrcardio.2012.6410.1038/nrcardio.2012.64 ↗
10. 10.1016/S0142-9612(99)00205-710.1016/S0142-9612(99)00205-7 ↗
11. 10.1021/bm800681k10.1021/bm800681k ↗
12. 10.1002/jbm.b.3277210.1002/jbm.b.32772 ↗
13. 10.1116/1.348321810.1116/1.3483218 ↗
14. 10.1023/A:101616270639110.1023/A:1016162706391 ↗
15. 10.1016/j.biomaterials.2007.11.00210.1016/j.biomaterials.2007.11.002 ↗
16. 10.1016/j.pathophys.2008.02.00210.1016/j.pathophys.2008.02.002 ↗
17. 10.1007/s00441-008-0659-810.1007/s00441-008-0659-8 ↗
18. 10.1007/3-540-32967-6_210.1007/3-540-32967-6_2 ↗
19. 10.1016/j.apsusc.2016.09.10710.1016/j.apsusc.2016.09.107 ↗
20. 10.1016/j.biomaterials.2010.09.01410.1016/j.biomaterials.2010.09.014 ↗
21. Endothelial cell attachment and spreading on human tenascin is mediated by alpha 2 beta 1 and alpha v beta 3 integrins10.1242/jcs.105.4.1001 ↗
22. 10.1021/bi00396a00410.1021/bi00396a004 ↗
23. 10.1080/0953710080208225610.1080/09537100802082256 ↗
24. 10.1021/am500121310.1021/am5001213 ↗
25. 10.1016/j.apsusc.2014.02.11910.1016/j.apsusc.2014.02.119 ↗
26. 10.1039/C4TB00386A10.1039/C4TB00386A ↗
27. 10.1016/j.colsurfb.2014.12.05610.1016/j.colsurfb.2014.12.056 ↗
28. Installing multifunctionality on titanium with RGD‐decorated polyurethane‐polyurea roxithromycin loaded nanoparticles: Toward new osseointegrative therapies
29. 10.1016/j.colsurfb.2014.12.05710.1016/j.colsurfb.2014.12.057 ↗
30. 10.1111/j.1600-0501.2012.02451.x10.1111/j.1600-0501.2012.02451.x ↗
31. 10.1016/S0049-3848(97)00014-510.1016/S0049-3848(97)00014-5 ↗
32. Detection of reactive oxygen species during the cell cycle under normal culture conditions using a modified fixed‐sample staining method
33. 10.1074/jbc.M00970520010.1074/jbc.M009705200 ↗
34. 10.1111/j.1365-3083.2008.02029.x10.1111/j.1365-3083.2008.02029.x ↗
35. 10.1016/j.biomaterials.2007.01.03910.1016/j.biomaterials.2007.01.039 ↗
36. 10.1016/S0021-9258(19)37117-010.1016/S0021-9258(19)37117-0 ↗
37. FerraraN Davis‐SmythT.The biology of vascular endothelial growth factor.2013;18:4–25.10.1210/edrv.18.1.0287 ↗
38. 10.1038/nrc215210.1038/nrc2152 ↗
39. 10.1242/jcs.0116510.1242/jcs.01165 ↗
40. Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets: effects on surface proteins and platelet aggregation10.1182/blood.V68.1.275.275 ↗
41. 10.1016/S0021-9258(19)81051-710.1016/S0021-9258(19)81051-7 ↗
42. 10.1084/jem.187.3.32910.1084/jem.187.3.329 ↗
43. New RGD analogue inhibits human platelet adhesion and aggregation and eliminates platelet deposition on canine vascular grafts10.1016/0741-5214(92)90016-2 ↗
44. ChenCS PapayannopoulosIA TimmonsS ChouSH ThiagarajanP.A modified Arg‐Asp‐Val (RDV) peptide derived during the synthesis of Arg‐Glu‐Asp‐Val (REDV) a tetrapeptide derived from an alternatively spliced site in fibronectin inhibits the binding of fibrinogen fibronectin von Willebrand factor and vitronectin t. BBA Gen Subj ASBMB1991;1075:237–247.10.1016/0304-4165(91)90272-I ↗
45. 10.1055/s-2007-100257110.1055/s-2007-1002571 ↗
46. Design and synthesis of RGD mimetics as potent inhibitors of platelet aggregation
47. Two‐step binding mechanism of fibrinogen to alpha IIb beta 3 integrin reconstituted into planar lipid bilayers10.1016/S0021-9258(18)53320-2 ↗
48. 10.1016/S0006-3495(00)76677-X10.1016/S0006-3495(00)76677-X ↗
49. 10.1016/0882-4010(89)90002-810.1016/0882-4010(89)90002-8 ↗
50. 10.1016/S0142-9612(03)00343-010.1016/S0142-9612(03)00343-0 ↗
51. 10.1038/309030a010.1038/309030a0 ↗
52. Covalently immobilized laminin peptide Tyr‐Ile‐Gly‐Ser‐Arg (YIGSR) supports cell spreading and colocalization of the 67‐kilodalton laminin receptor with α‐actinin and vinculin10.1016/S0021-9258(18)53062-3 ↗
53. 10.1002/(SICI)1097-4644(19971101)67:2<155::AID-JCB1>3.0.CO;2-W10.1002/(SICI)1097-4644(19971101)67:2<155::AID-JCB1>3.0.CO;2-W ↗
54. 10.1016/j.biomaterials.2004.02.01210.1016/j.biomaterials.2004.02.012 ↗